NCT01521390View on ClinicalTrials.gov

Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler.

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 12, 2011

Primary Completion Date

December 16, 2011

Study Completion Date

December 16, 2011

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

GSK573719 62.5 mcg (one strip)

GSK573719 62.5 mcg delivered by 1 strip configuration of novel dry powder inhaler

DRUG

GSK573719 62.5 mcg(two strips)

GSK573719 62.5 mcg delivered by 2 strip configuration of novel dry powder inhaler

DRUG

GSK573719 125 mcg (one strip)

GSK573719 125 mcg delivered by 1 strip configuration of novel dry powder inhaler

DRUG

GSK573719 125 mcg(two strips)

GSK573719 125 mcg delivered by 2 strip configuration of novel dry powder inhaler

DRUG

Placebo

Placebo, no active ingredient

Trial Locations (1)

14050

GSK Investigational Site, Berlin

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01521390 - Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler. | Biotech Hunter | Biotech Hunter